The epidemiology of oral cancer during the COVID-19 pandemic in Northern Italy: Incidence, survival, prevalence

Lucia Mangone1, Pamela Mancuso1, Isabella Bisceglia1*, Giacomo Setti2, Giuliano Malaguti3 and Paolo Giorgi Rossi1

1Epidemiology Unit, Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, Italy, 2Centro Universitario Odontoiatria, University of Parma, Parma, Italy, 3Department of Specialist Surgeries Head-Neck, Modena and Reggio Emilia University, Modena, Italy

Despite novel treatment approaches, oral cancer survival has not improved significantly and the disease often presents a disabling path for patients. The aim of this work was to describe the epidemiological data of oral cancers in a province of northern Italy. Incident cases in the period 1996–2020 and EU population standardized rates were reported for Oral Cavity cancer (OC) and OroPharyngeal cancer (OP). Annual percent changes (APC) were estimated with joint point analysis. The 5-year survival was calculated in three different periods: 1996–2000, 2001–2010 and 2011–2015. From 1996 to 2020, 771 cases of oral cancers (442 OC and 329 OP) were recorded with the age-standardized incidence rate 7.28 (10.74 in males and 3.97 in females): 3.82 for OC and 3.47 for OP. In males there is a significant increase in the incidence of OP up to 2017 (APC 11; 95% CI, 4.9–17.5), which then decreases; in females the rates are constant. In 2020 (the era of Covid-19), we did not see a decline in incidence compared to 2019. The 5-year survival (for cases diagnosed in 2011–2015) was 55.6%, 56.5% and 56% for OC, OP and OC + OP, respectively; it was somewhat higher in females and was undergoing some changes over the course of years. The number of prevalent cases as of 1 January 2021 is 314 (175 OC, 139 OP). The study showed a decline in cancers in men, particularly for OP; survival shows improvement in the long-term examined; Covid-19 had no negative impact on 2020 diagnoses.

KEYWORDS
oral cancer, incidence, survival, prevalence, COVID-19

Introduction

Tumors of the oral cavity are infrequent neoplasms but they represent an underestimated public health problem (1). Incidence rate considering all subsites together (oral cavity including lips, pharyngeal region, ICD_O III edition C00–C14) (2) is about 500,000 yearly cases globally. Oral cavity and oropharynx are contiguous organs with distinct embryological origin and proven differences in cancer development (3). Confusion in groupings due to variations in subsites attribution is affecting the literature. Therefore, a quantitative analysis of disease relies on clear and
uniform definitions which include topography (site), morphology (histopathology), and tumor behavior (invasive—malignant, benign, in-situ). To date, there is a large consensus that oral cancer should be recognized as being two distinct diseases: Oral Cavity cancer (OC) and OroPharyngeal cancer (OP) (4). This clarification is necessary to better understand the attributable fraction to HPV (Human Papilloma Virus) infection (5), alongside the well-known risk factors such as smoking and alcohol (6).

The association with risk factors has been known for some time: in fact, tumors of the oral cavity are largely linked to the consumption of alcohol and tobacco smoke (7–9) while tumors of the oropharynx are largely linked to HPV infection (10–12).

In addition to exposure to risk factors, the sharing of morphology also unites these tumors: squamous cell carcinoma (SCC) accounts for 90%–95% of OCs (13). It may arise ex novo or from a potentially malignant disorder (PMD, lesions with increased risk of cancer development that can exhibit different grade of dysplasia) and usually spreads locally invading surrounding structures. The lower lip, oral tongue, floor of the mouth and retro molar trigone are the malignancy outbreak site in more than 75% of SCC cases. Disease biological behavior directly affects progression and prognosis worsening. Extension and depth of invasion define the T stage according to TNM classification, nodes metastases represent a pitfall for prognosis (15). The survival rate drops dramatically from about 90% to 25%–40% at 5-years when loco-regional nodes are involved (3). Known risk factors are smoking, alcohol drinking and HPV (16–20). Incidence peaks after the age of 70 and it is much higher in males (13).

OP commonly arise in the tonsils and the tongue base, with a poorly differentiated form of SCC, locally advanced at the time of clinical presentation (14). Known risk factors are the same as OC, but HPV infection is responsible for a larger proportion of cancers in OC than in OP. Worldwide, the estimated HPV-attributable portion of oropharyngeal cancer is less than 30% but numbers are expected to increase (16). Patients with HPV-positive OP are more likely to present with small primary tumors and extensive nodal disease. Even with the early nodes involvement, 5-year survival rate is higher in such patients compared to HPV-negative cases (17). HPV-positive cancers usually occur in younger male patients, and the role of smoking and alcohol as risk factors is smaller.

Even if there are still some critical issues regarding risk factor awareness among the target population, it is important to increase data sharing and knowledge, to help improve the level of awareness and assessment of risk factors for oral cancer (21).

In Italy there are no epidemiological data on the incidence of oral cancers and in particular there is a lack of recent data. The estimates to 2018 are projections of the incident years in 2003–2014: incidence and mortality decrease in males and appear to slightly increase in females (22).

The aim of this work is to describe the incidence data, survival and prevalence of oral cancer in a province of northern Italy and, with the availability of data for 2020, also evaluate the impact of Covid-19 on new cancer diagnoses.

### Materials and methods

#### Data source

This is a population-based cohort study using data from the Reggio Emilia Cancer Registry (RE-CR) approved by the provincial Ethics Committee of Reggio Emilia (Protocol n. 2014/0019740 of 04/08/2014). Reggio Emilia is a province in northern Italy with about 532,000 inhabitants.

The RE-CR registers all new cancer diagnoses occurring in people residing in the Reggio Emilia Province. The main information sources are the anatomic pathology reports, the hospital discharge records, and mortality data from the RE-CR. The RE-CR, which covers the entire resident population in the Province of Reggio Emilia, has been active since 2000 and registered all incident cases from 1996 to 2020, with an active follow up for deaths and residence of all prevalent cases updated up to 01/01/2021. It collects information on site, morphology, type of diagnosis, survival and prevalence (23).

#### Definitions of oral cancer

According to the International Classification of Diseases in Oncology (ICD-O III edition) we have classified tumors using the following criteria. **Oral cavity cancer** includes: the inner lip (C00.3–C00.9), other and unspecified parts of the tongue (C02) (excluding lingual tonsil [C2.4]), gum (C03), floor of the mouth (C04), palate (C05), and other and unspecified parts of the mouth (C06) (2).

To allow easy comparison with other recent data, we grouped oral cancers according to a definition proposed by Conway (4). **Oropharyngeal cancer** includes: the base of the tongue (C01), lingual tonsil (C2.4), tonsil (C09), oropharynx (C10), and pharynx unspecified including Waldeyer’s ring/overlapping sites of oral cavity and pharynx (C14).

In addition to the classification by site, the morphologies of the tumors have been defined, as reported in the ICD-O III edition classification, in this case the tumors include all the indicated morphologies, including for example the NHL of the Waldeyer’s ring.

#### Data analyses

Only infiltrating malignant tumors from subjects residing in the province of Reggio Emilia at the time of diagnosis were
Results

From 1996 to 2020, 771 cases of oral cancers, 442 OC and 329 OP were recorded. The average age is around 65.5 years, it affects males more, with a M: F ratio of 2:1. In the study period, divided into five years, there was an increase in cases: it went from 107 in 1996–2000 to 174 in 2016–2020. The sites for which a higher number of cases are recorded are: for OC, the dorsal surface of the tongue (124 cases), mouth (86 cases) and overlapping lesions of the tongue (53 cases); for OP the majority of cases are recorded for the tonsils (184 cases) (Table 1).

With regard to morphology, the squamous forms are 84.8% for OC and 80.9% for OP; in the latter category, 11.9% of tumors are lymphomas.

The age-standardized incidence rate was 7.28 in 2020 (10.74 in males and 3.97 in females), higher than that recorded in 2019 of 5.60 (10.36 in males and 1.33 in females). Considering the sub-locations in the last period, already affected by the Covid-19 pandemic, the rates were 3.82 for OC and 3.47 for OP in 2020, respectively higher than the 2.62 and 2.97 recorded in 2019 (Table 2).

In males, the OP incidence trend increased statistically until 2007 and then decreased; in the last two years, we report a high number of OP cancers, but this increase is compatible with a random fluctuation. OC showed a sharp increase from 1996 to 2000 and then a plateau (Figure 1). In females, the incidence was steady over the period for both OC and OP.

The 5-year survival for OC + OP was 51.2% (95% CI, 41.3–60.2), 50.7% (95% CI, 45.2–56.0) and 56.0% (95% CI, 47.7–63.4) in the three periods considered (Table 3 and Figure 2). For OC, survival went from 52.6% (95%CI, 39.9–63.9) to 45.1 (95% CI, 37.5–52.3) to 55.6 (95% CI, 45.0–65.0). Survival for OP goes from 48.8% (95% CI, 32.9–62.9) to 57.1% (95% CI, 48.9–64.4) to 56.5% (95% CI, 43.0–68.1).

The number of prevalent live cases as of January 1, 2021 is 314 (175 OC, 139 OP): there are twice as many males as there are females. Among OC, patients with diagnoses between 2 and 9 years prevail while among OP, patients with diagnoses over 9 years prevail (Table 4).

Discussion

In our study, we observed a 3.8/100,000 and 3.5/100,000 incidence of oral cavity and oropharynx cancer, respectively, with an age standardized M: F ratio of approximately 2.6:1 and 2.8:1 for OC and OP, respectively. Globally, comparing the data published worldwide by GLOBOCAN (27) in 2012, the estimated age-standardized rate was about 4/100,000: 2.7 per 100,000, for OC and 1.4/100,000 for OP. The worldwide incidence is consistently higher in men than in females with a M: F ratio of 2:1 and 4.8:1 for OC and OP, respectively (28).

For OP, our observed incidence is among the highest in Europe for both males and females. For OC, incidence rates are comparable with those observed in other high income countries for both males and females (28).

In males, we observed an increase in the initial period for both OC and OP, then a plateau was observed for OC, while OP significantly decreased until 2017. In females, there were no appreciable changes in incidence over the study period for both OC and OP. In the literature, the incidence of oropharyngeal cancer is rapidly increasing, especially in high-income countries and especially in the United States (29–30). In contrast, oral cavity cancer incidence rates are stable or decreasing in men globally and slightly increasing in women (31). In England, between 1995 and 2011, the OC recorded an annual increase of 2.8% in males and 3.0% in females, while for OP the APC was 7.3% in men and 6.5% in women (32). In Scotland, between 2001 and 2012, the OP increased by 85% and the OC only by 10%. These trends were found to be more pronounced in men (32–34) and in most deprived areas (33). These trends are consistent with the different relative weight of the three main risk factors in OC and OP: the prevalence of HPV infection, that is more important in OP than OC, increased in the last decades in highest income countries (35–36) and in Italy (37); smoking and drinking alcohol were higher in men in the highest income countries
but, at least smoking, decreased more rapidly in the last decades in men than in women (38).

Finally, it is worth noting that many studies reported an impact of the Covid-19 pandemic on the number of cancer diagnoses. In particular, a recent research carried out in Italy, in particular in the metropolitan area of Turin (39), found that compared to the seven cases expected in the period under study, only one case of oral squamous cell carcinoma (OSCC) was diagnosed. The authors suggest that this is because dentists have postponed less critical interventions (39). In our study we did not observe any decrease in the number of cancers which occurred in 2020 compared to that expected based on the incidence of previous years, as can be seen in Figure 1.

As for survival, there was a slight increase in the last period for both cancers, but this improvement was largely compatible with random fluctuation. Considering the sub-sites, survival for OC is higher in males than in females and the opposite is true for OP. In the Montero study (40), from 1960 to 2012, a survival increase of 15% was recorded (it went from 48% in

| TABLE 1 Distribution of 771 patients with oral cancer, by age, sex, years of diagnosis, site and morphology. |
|---------------------------------------------------------------|-----------------|-----------------|-----------------|
| Oral cavity cancer                                           | Oropharyngeal cancer | Total           |
| n                  %                        | n                  %                        | n                  |
| Overall            442                      | 329                | 771             |
| Age (mean. sd)     66.9 (14.4)            | 63.5 (13.1)        | 65.5 (13.9)     |
| Sex                |                      |                  |                  |
| Male               279                      | 63.1               | 233              | 70.8            | 512 |
| Female             163                      | 36.9               | 96              | 29.2            | 259 |
| Year               |                      |                  |                  |                  |     |
| 1996–2000          66                  | 14.9               | 41              | 12.5            | 107 |
| 2001–2005          89                  | 20.1               | 60              | 18.2            | 149 |
| 2006–2010          87                  | 19.7               | 96              | 29.2            | 183 |
| 2011–2015          97                  | 21.9               | 61              | 18.5            | 158 |
| 2016–2020          103                 | 23.3               | 71              | 21.6            | 174 |
| Site               |                      |                  |                  |                  |     |
| Lip (C00.3–C00.9)  28                  | 6.3               |                  |                  |     |
| Dorsal surface of tongue. NOS (C02.0–C02.3)                 | 124              | 28.1           |                  |     |
| Overlapping lesion of tongue or tongue NOS (C02.8–C02.9)    53                  | 12.0               |                  |                  |     |
| Gum (C03)          41                  | 9.3               |                  |                  |     |
| Floor of mouth (C04) 45                          | 10.2               |                  |                  |     |
| Soft palate (C05.1) 29                             | 6.6               |                  |                  |     |
| Uvula (C05.2)      2                       | 0.5               |                  |                  |     |
| Overlapping lesion of palate or palate NOS (C05.8)           0                       | 0.0               |                  |                  |     |
| Cheek mucosa (C06.0) 34                             | 7.7               |                  |                  |     |
| Overlapping lesion and unspecified mouth (C06.8–C06.9)       86                     | 19.5              |                  |                  |     |
| Base of tongue. NOS (C01.0–C1.09)                        101             | 30.7               |                  |                  |     |
| Lingual tonsil (C02.4)                                    4                       | 1.2               |                  |                  |     |
| Tonsil (C09)       184                 | 55.9               |                  |                  |     |
| Anterior surface of epiglottis (C10.1)                     3                       | 0.9               |                  |                  |     |
| Lateral wall of oropharynx (C10.2)                        11                     | 3.3               |                  |                  |     |
| Pharynx unspecified and overlapping (C14.0)                 24                     | 7.3               |                  |                  |     |
| Waldeyer’s ring (C14.2)                                   2                       | 0.6               |                  |                  |     |
| Morphology         | 442                      | 329                | 100              | 771             |
| Carcinoma          41                  | 9.3                | 20              | 6.1             | 61 |
| Squamous cell      375                 | 84.8               | 266              | 80.9            | 641 |
| Adenocarcinoma     23                  | 5.2                | 4                | 1.2             | 27 |
| Lymphomas          3                     | 0.7               | 39              | 11.9            | 42 |

Mangone et al. 10.3389/froh.2022.982584
### TABLE 2 Age-standardized incidence rate by subtype and sex. 2020 vs. 2019.

|                      | 2019     | 2020     | 2019     | 2020     |
|----------------------|----------|----------|----------|----------|
|                      | Incidence | Incidence | Age-standardized | Age-standardized |
|                      | rate      | rate     | incidence ratea| incidence ratea |
| Oral cavity cancer (OC) | 15 2.82   | 22 4.15  | 2.62      | 3.82      |
| Male                 | 13 4.97   | 15 5.75  | 4.96      | 5.56      |
| Female               | 2 0.74    | 7 2.60   | 0.56      | 2.12      |
| Oropharyngeal cancer (OP) | 17 3.20   | 20 3.78  | 2.97      | 3.47      |
| Male                 | 14 5.35   | 14 5.37  | 5.40      | 5.17      |
| Female               | 3 1.11    | 6 2.23   | 0.76      | 1.85      |
| Oral cavity and Oropharyngeal cancer (OC-OP) | 32 6.02 | 42 7.93 | 5.60 | 7.28 |
| Male                 | 27 10.32  | 29 11.12 | 10.36     | 10.74     |
| Female               | 5 1.85    | 13 4.83  | 1.33      | 3.97      |

*aEUROPE 2013.*

### FIGURE 1
Trends in European age-standardized incidence rates of oral cavity cancer (OC) and oropharyngeal cancer (OP), males and females (1996–2020).
the period 1960–1964 to 63% in 1985–2012). In addition, in this study it was also shown that 5-year survival ranged from 78.5% for stage I to 34.5% for stage IV (41), confirmed by rates of only 10%–40% (42–43). It is reported in the literature that two thirds of OC (41–43) cases are diagnosed in advanced stages (stage III or IV) (43), when 5-year survival is less than 50% (44). In stages I and II, oral squamous carcinoma injuries may not cause any

### TABLE 3 Five-year survival by subtype, sex and period. Years 1996–2015.

|                      | 1996–2000 |                      | 2001–2010 |                      | 2011–2015 |
|----------------------|-----------|----------------------|-----------|----------------------|-----------|
|                      | 5-years IC 95% |                      | 5-years IC 95% |                      | 5-years IC 95% |
| Oral cavity cancer (OC) | 52.6% 39.9% 63.9% | 45.1% 37.5% 52.3% | 55.6% 45.0% 65.0% |
| Male                 | 59.5% 42.0% 73.2% | 43.6% 34.2% 52.5% | 56.3% 42.2% 68.3% |
| Female               | 43.6% 25.2% 60.6% | 47.8% 34.9% 59.6% | 54.7% 38.0% 68.6% |
| Oropharyngeal cancer (OP) | 48.8% 32.9% 62.9% | 57.1% 48.9% 64.4% | 56.5% 43.0% 68.1% |
| Male                 | 44.4% 25.6% 61.8% | 56.3% 46.6% 64.9% | 53.9% 38.4% 67.1% |
| Female               | 57.1% 28.4% 78.0% | 59.1% 43.2% 71.9% | 66.7% 37.5% 84.6% |
| Oral cavity and Oropharyngeal cancer (OC-OP) | 51.2% 41.3% 60.2% | 50.7% 45.2% 56.0% | 56.0% 47.7% 63.4% |
| Male                 | 53.1% 40.3% 64.4% | 49.9% 43.2% 56.3% | 55.1% 44.8% 64.2% |
| Female               | 48.1% 32.5% 62.1% | 52.5% 42.6% 61.5% | 57.8% 43.5% 69.6% |

![FIGURE 2](image_url)  
Five-year survival by subtype and sex in three different periods.
symptoms or discomfort; therefore, the patient does not go to the dentist or other specialists until the pathological condition becomes more serious and difficult to treat (45). Untreated patients with metastatic disease show a survival of about 4 months (41).

Another problem has been the lack of consensus in the literature on the definitions of oral cancer, often different terms have been used to identify these neoplasms. The terminology “head and neck cancer” has also complicated the approach of the scientific and clinical community to these cancers. Oral cancer is now increasingly recognized as two different diseases: cancer of the oral cavity and of the oropharynx. This debate on definitions also emerged in a 2018 English study (4). Considering these two sites separately, OC accounts for approximately 377,000 new diagnoses and 177,000 deaths per year worldwide; OP is diagnosed about 100,000 cases a year and accounts for nearly 50,000 deaths (46–47).

As a consequence of the difficulty in the exact definition of the cases and of the terms used, the estimation of prevalent cases can also be difficult (48). Given the low incidence of the disease and its low survival rate, there are few live cases with previous diagnosis: in our province just over 300 cases. This is important, since the management of patients with oral cancer must consider not only new incident cases and pay attention to precancerous lesions, but must also consider the risk of local recurrence, which represents one of the major challenges in managing these patients. Among the limitations of the study we report that we have no indications on risk factors (smoking, alcohol and HPV infection) and we have no data on the stage of the disease.

Among the strengths, we mention the availability of 25 years of incidence, the absence of selection bias because they are population-based data and above all the availability of a year as recent as 2020, which had already been affected by the new pandemic situation.

TABLE 4 Prevalence at first January 2021 by subtype, sex and years by diagnosis.

| Years by diagnosis | <2 | 2–9 | 9+ | All |
|--------------------|----|-----|----|-----|
| Oral cavity cancer (OC) | 23 | 50 | 39 | 112 |
| Male | 6 | 32 | 25 | 63 |
| Female | 22 | 25 | 50 | 97 |
| Oropharyngeal cancer (OP) | 8 | 16 | 18 | 42 |
| Male | 45 | 75 | 89 | 209 |
| Female | 14 | 48 | 43 | 105 |

Conclusion

In conclusion, the availability of recent and long-term data can help clinicians and stakeholders to have greater awareness of the trend of oral cancers. Diagnostic and terminology difficulties on the one hand and changes in risk factors on the other (smoking and HPV in particular) account for the rapid changes we are observing. Covid-19, at least in our province, does not seem to have had a negative impact on new diagnoses.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

This population-based cohort study uses data from the Reggio Emilia Cancer Registry, approved by the Provincial Ethics Committee of Reggio Emilia (ref. no. 2014/0019740 of 4 August 2014). The Ethics Committee authorized, even in the absence of consent, the processing of personal data, including those suitable for revealing the state of health of patients who are deceased or untraceable for the execution of the study.

Author contributions

Conceptualization, investigation, writing—original draft, visualization, supervision, LM; formal analysis, PM; writing—review and editing, and visualization, IB; investigation, supervision GM; investigation and supervision GS; conceptualization, writing—original draft, investigation, and supervision, PGR. All authors have read and agreed to the published version of the manuscript.

Funding

This study was partially supported by Italian Ministry of Health - Ricerca Corrente Annual Program 2023 and partially funded by the Emilia Romagna Health Authority, grant number (DRG 396; DRG 1800/2020).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. The Oral Cancer Foundation. Oral cancer facts. Available from: https://oralcancerfoundation.org/facts/ (Accessed May 3, 2022).

2. Fritz AG. International classification of diseases for oncology: ICD-O. 3rd ed. Geneva, Switzerland: World Health Organization (2000).

3. American Cancer Society. Facts & figures 2021. Atlanta, GA: American Cancer Society (2021).

4. Conway DJ, Purkayastha M, Chestnutt IG. The changing epidemiology of oral cancer: definitions, trends, and risk factors. Br Dent J. (2018) 224(9):867-73. doi: 10.1038/sj.bdj.2018.922

5. Tulay P, Serakinci N. The role of human papillomviruses in cancer progression. J Cancer Metastasis Treat. (2016) 2:201-13. doi: 10.20517/2394-4722.2015.67

6. Elbashy OA, Ashry R, Tran SD. Head and neck cancer management and cancer stem cells implication. Saudi Dent J. (2019) 31(4):395-416. doi: 10.1016/j.sdentj.2019.05.010

7. Blot WJ, McLaughlin JK, Wynn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. (1988) 48(11):3282-7. PMID: 3365770

8. Toygas AJ, Estève J, Raymond L, Berrino F, Benhamou E, Blanchet F, et al. Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer. (1988) 41(4):483-91. doi: 10.1002/ijc.2910403

9. Hashibe M, Brennan P, Chuaug SC, Bocca S, Castellassaque X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis of the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. (2009) 18(2):541-50. doi: 10.1158/1055-9965.EPI-08-0347

10. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Active and involuntary tobacco smoking and upper aerodigestive tract cancer. Br Dent J. (2008) 254(8):407. doi: 10.1038/sj.bdj.2008.1655

11. Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D’Souza G, Gravett PE, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head and Neck. (2009) 31(11):1393-422. doi: 10.1002/hed.21269

12. Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factors profiles for human papillomavirus type 16-positive and human papillomavirus type-16 negative head and neck cancers. J Natl Cancer Inst. (2008) 100(6):407-20. doi: 10.1093/jnci/djn025

13. Watters C, Bear S, Pepper T. Oral Mucosa Cancer. [Updated 2021 Apr 13]. In: StatPearls. Treasure Island, FL: StatPearls Publishing (2022).

14. Vogel TWD, Zabrean P, Thoeny HC. Cancer of the oral cavity and oropharynx. Cancer Imaging. (2010) 10(1):62-72. doi: 10.1047/j.1740-7330.2010. 0008

15. Brasher JD, Gospodarowicz MK, Wittkind C (eds). TNM Classification of malignant tumours. 8th ed. Chichester: John Wiley and Sons (2017).

16. Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. (2015) 8(9):11848-94. PMID: 26617944; PMCID: PMC4637760

17. Gandini S, Botteri E, Iodice S, Benoni M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. (2008) 122(1):155-64. doi: 10.1002/ijc.23033

18. Lee YC, Marron M, Benhamou S, Bouchard C, Ahrens W, Polhabel H, et al. Active and involuntary tobacco smoking and upper aerodigestive tract cancer risks in a multicenter case-control study. Cancer Epidemiol Biomarkers Prev. (2009) 18(12):3535-42. doi: 10.1158/1055-9965.EPI-09-0910

19. Kumar M, Nanavati R, Modi TG, Doharaya C. Oral cancer: etiology and risk factors: a review. J Cancer Res Ther. (2016) 12(2):458-63. doi: 10.4103/0973-1482.186696

20. Jafarey NA, Mahmood Z, Zaidi SH. Habits and dietary pattern of cases of carcinoma of the oral cavity and oropharynx. J Pak Med Assoc. (1977) 27(6):340-3. PMID: 413946

21. Amer HW, Wahed AA, Badawi OA, Emara AS. Oral cancer awareness level within the dental community: results from a large scale survey in cairo. J Cancer Educ. (2018) 33(6):1279-84. doi: 10.1007/s13187-017-1243-3

22. AIFOM, AIRTUM, PASSI. I numeri del cancro in Italia 2018. Intermedia Editore Brescia (2018).

23. Cancer Incidence in Five Continents Volume XI. IARC Scientific Publication No. 166. Edited by Bray F, Zambonini G, Chabateau A, Bray F, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subtype in 2012. CA Cancer J Clin. (2017) 67(1):51-64. doi: 10.3322/caac.21384

24. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. (2013) 31(3):235-42. doi: 10.1200/JCO.2012.49.0919

25. Mehanah H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, et al. The prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer: systematic review and meta-analysis of trends by time and region. Head Neck. (2013) 35:747-55. doi: 10.1002/hed.22015

26. Chaturvedi AK, Anderson WF, Lorret-Tieulent J, Carrado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. (2013) 31(4):550-9. doi: 10.1200/JCO.2013.50.8870

27. Louie KS, Mehanna H, Sasiem J. Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncol. (2015) 51:341-4. doi: 10.1016/j.oraloncology.2015.01.002

28. Purkayastha M, McMahon AD, Gibson J, Conway DJ. Trends of oral cavity, oropharyngeal and laryngeal cancer incidence in Scotland (1975–2012) – A socioeconomic perspective. Oral Oncol. (2016) 61:70-5. doi: 10.1016/j.oraloncology.2016.08.015

29. Junor EI, Kerr GR, Brewster DH. Oropharyngeal cancer. Fastest increasing cancer in Scotland, especially in men. Br Med J. (2010) 340:c2512. doi: 10.1136/bmj.c2512

30. Faraji F, Rettig EM, Tsai HL, El Asmar M, Fung N, Eisele DW, et al. The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status. Cancer. (2019) 125(5):761-9. doi: 10.1002/cncr.31841

31. Ellington TD, Henley SJ, Senkomago V, O’Neil ME, Wilson RJ, Singh S, et al. Trends in incidence of cancers of the oral cavity and pharynx – United States 2007-2016. MMWR Morb Mortal Wkly Rep. (2020) 69(15):433-8. doi: 10.15585/mmwr.mm6915a1

32. Del Mistro A, Frayle H, Menegaldo A, Favaretto N, Gori S, Nicolai P, et al. Age-independent increasing prevalence of Human Papillomavirus-driven oropharyngeal carcinomas in North-East Italy. Sci Rep. (2020) 10(1):9320. doi: 10.1038/s41598-020-66323-z

33. Institute for Health Metrics and Evaluation (IHME). GBDS Compare data visualization. Seattle, WA: IHME, University of Washington (2020).
39. Arduino PG, Conrotto D, Broccoletti R. The outbreak of Novel Coronavirus disease (COVID-19) caused a worrying delay in the diagnosis of oral cancer in north-west Italy: The Turin Metropolitan Area experience. Oral Dis. (2021) Suppl 3(Suppl 3):742–3. doi: 10.1111/odi.13362

40. Montero PH, Patel SG. Cancer of the oral cavity. Surg Oncol Clin N Am. (2015) 24(3):491–508. doi: 10.1016/j.soc.2015.03.006

41. Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer. (2000) 36:1032–7. doi: 10.1016/S0959-8049(00)00054-X

42. Yao M, Epstein JB, Modi BJ, Pytynia KB, Mundi AJ, Feldman LE. Current surgical treatment of squamous cell carcinoma of the head and neck. Oral Oncol. (2007) 43:213–23. doi: 10.1016/j.oraloncology.2006.04.013

43. Guneri P, Epstein JB. Late stage diagnosis of oral cancer: components and possible solutions. Oral Oncol. (2014) 50:1131–6. doi: 10.1016/j.oraloncology.2014.09.005

44. Viet CT, Schmidt BL. Biologic mechanisms of oral cancer pain and implications for clinical therapy. J Dent Res. (2012) 91:447–53. doi: 10.1177/0022034511424156

45. Rodríguez-Archilla A. Diagnostic Delay in Oral Cancer (2017). Available from: https://scientonline.org/abstract/21675/Diagnostic-Delay-in-Oral-Cancer (Accessed July 1, 2022).

46. The National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Cancer stat facts: oral cavity and pharynx cancer. Available from: https://seer.cancer.gov/statfacts/html/oralcav.html (Accessed August 20, 2020.)

47. Ferlay J, Colombet M, Soerjomataram I, Parkin MD, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. (2021) 149:778–89. doi: 10.1002/ijc.33588

48. Inchingolo F, Santacroce L, Ballini A, Topi S, Dipalma G, Hazireh K, et al. Oral cancer: a historical review. Int J Environ Res Public Health. (2020) 17(9):3168. doi: 10.3390/ijerph17093168